Gina Mauro

Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

FDA Approves Fruquintinib for Metastatic Colorectal Cancer-Audio Test

November 8th 2023

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

BXCL701/Pembrolizumab Combo Prolongs OS in mCRPC of Adenocarcinoma Phenotype

November 8th 2023

Treatment with the oral innate immune activator BXCL701 combined with pembrolizumab demonstrated prolonged overall survival in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype.

FDA Approves Ivosidenib for Relapsed/Refractory IDH1-Mutant MDS

October 24th 2023

The FDA has approved ivosidenib (Tibsovo) for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21st 2023

Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.

At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma

September 28th 2023

Mezigdomide in combination with either bortezomib and dexamethasone or carfilzomib and dexamethasone showed encouraging responses across multiple dose levels in patients with relapsed/refractory multiple myeloma.

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups

July 14th 2023

The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.

FDA Approves Glofitamab-gxbm for Relapsed/Refractory DLBCL

June 16th 2023

The FDA has approved glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.

Persistence Is Key to Success

June 15th 2023

Vinay Edlukudige Keshava, MD, shares the story of his fellowship and provides advice on how to best transition to the next step in an oncologic career.

UT Southwestern Fellows Embrace Creativity in Managing Patient Diversity and Cancer Care

June 13th 2023

Amy Jones, MD, details the socioeconomic challenges with patients coming into the Dallas County clinics and how oncology fellows become equipped to address them.

Gilteritinib Shows RFS Benefit as Maintenance, Posttransplant Therapy in MRD+ FLT3-Mutant AML

June 11th 2023

Gilteritinib led to a 48% reduction in disease recurrence for patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease pre and post hematopoietic stem cell transplant compared with placebo, highlighting a role for treatment in this subgroup of patients.

Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

June 10th 2023

Ruxolitinib was found to improve spleen volume and tumor symptom score in patients with myelofibrosis, irrespective of their anemia and transfusion status, according to data from a post-hoc analysis of the phase 3 COMFORT-I and -II trials.

Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC

June 5th 2023

The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.

Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023

Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

Obecabtagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer

June 2nd 2023

Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

May 25th 2023

Minimally invasive distal pancreatectomy was found to be a safe and effective alternative to that of open distal pancreatectomy in patients with resectable pancreatic cancer, confirmed by a noninferior radical resection rate, lymph node yield, and comparable survival data.

NDA Submitted for Rivoceranib/Camrelizumab Combo in Frontline Unresectable HCC

May 17th 2023

A new drug application has been submitted to the FDA for the combination of rivoceranib and camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.

Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC

April 28th 2023

Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.

ALLO-316 Demonstrates Antitumor Activity in Advanced Clear Cell RCC

April 17th 2023

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.